ObjectiveComparative study of the efficacy, adverse reactions and the effects of Robaplatin and Cisplatin onperipherd blood Circulation tumor cells in patients with malignant pleural effnsion. Methods84 patients with advanced lung cancer and malignant hydrothorax were randomly divided into lobaplatin group and cisplatin group, 42 cases in each group. Patients in both groups underwent pleurodesis (intercostal intercostal drainage and pleurodesis) after chemotherapy with gemcitabine cisplatin. The lobaplatin group were treated with lobaplatin in the thoracic cavity and cisplatin in the cisplatin group once a week. The clinical efficacy, quality of life, CTC levels in peripheral blood before and after treatment, and adverse reactions occurred in the two groups were compared after 2 times of perfusion. ResultsThe treatment efficiency of the patients in the lobaplatin group (76.2%) was significantly higher than that in the cisplatin group (52.4%), and the difference was statistically significant (P＜0.05). The improvement rate of quality of life in the lobaplatin group (57.1%) was significantly higher than that in the cisplatin group (23.8%), and the difference was statistically significant (P＜0.05). After 2 months′ pleural adhesion, the CTC levels in the two groups were significantly decreased (P＜0.05). The CTC level in the lobaplatin group was slightly lower than that in the cisplatin group, but the difference was not statistically significant (P＞0.05). The incidence of adverse reactions was significantly lower in the lobaplatin group than in the cisplatin group (P＜0.05). ConclusionChemotherapy combined with lobaplatin pleurodesis in the treatment of patients with advanced lung cancer complicated with malignant hydrothorax was significantly higher than the combination of cisplatin treatment, and the toxicity was mild, which can effectively alleviate the clinical symptoms and improve the quality of life.

无